Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | PNPLA2 | Q96AD5 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | TGM2 | P21980 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | APEX1 | P27695 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7618218 | 0.88 | GAA (0.58) | GAARAB9ASMN1; SMN2TGM2MEN1 | |
| SCHEMBL19019393 | 0.87 | TP53 (0.69) | TP53PNPLA2HDAC6APEX1 | |
| SCHEMBL8153658 | 0.80 | HSD17B10 (0.65) | TP53PNPLA2HDAC6SMN1; SMN2MEN1 | |
| SCHEMBL11164480 | 0.80 | TP53 (0.61) | TP53PNPLA2HDAC6APEX1 | |
| SCHEMBL20057568 | 0.80 | TP53 (0.61) | TP53PNPLA2HDAC6APEX1 | |
| SCHEMBL10425058 | 0.80 | ALDH1A1 (0.65) | TP53PNPLA2HDAC6RAB9AMEN1 | |
| SCHEMBL264735 | 0.79 | GAA (0.66) | GAARAB9ASMN1; SMN2TGM2ALDH1A1 | |
| SCHEMBL2150418 | 0.79 | CA12 (0.63) | GAARAB9ASMN1; SMN2TGM2MEN1 | |
| SCHEMBL19707566 | 0.79 | GAA (0.65) | GAARAB9ATGM2MEN1KMT2A | |
| SCHEMBL9128067 | 0.79 | TSHR (0.46) | TP53MEN1KMT2AAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180305231-A1 | COMPOSITE, A METHOD OF MAKING THEREOF, AND A METHOD FOR DEGRADING A POLLUTANT | KING ABDULAZIZ UNIVERSITY (SA) | 2018-10-25 | — | — | US | disclosed |
| WO-2014186704-A2 | NOVEL COMPOUNDS FOR THE TREATMENT OF CYSTIC FIBROSIS | N30 PHARMACEUTICALS, INC. (US) | 2014-11-20 | — | — | WO | disclosed |
| EP-2616071-A2 | FATTY ACID SYNTHASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2013-07-24 | — | — | EP | disclosed |
| US-20130172384-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | 2013-07-04 | — | — | US | disclosed |
| WO-2012037299-A2 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | WO | disclosed |
| US-4678503-A | STABILIZERS FOR HERBICIDES | RHONE-POULENC AGROCHIMIE (FR) | 1987-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172384-A1 | FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | GAA 1730/4885TP53 1755/4885PNPLA2 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.